img/92-35_files/92-3500001im.jpg" width="718" height="1067" useMap="#Map">
Neurological Basis of Behavior (PSY - 610)
VU
Lesson35
Basic Neurochemistry
Objectives:
To familiarize the students with the
Various NT and their role in the modulation of behaviors
Classification  of  Neurotransmitters.  Monoamines:  Catechoalimnes
and
Indolemaine,
acetylcholine, amino acid, and Peptide
Neurotransmitters role in modulation of behaviors and Aberration
Drugs and Behavior:
Classification of Psychopharmacological substances
Behavioral correlates, Treatment:
Mechanism of synaptic transmission
Main purpose:
We continue our discussion on the control and involvement of 5HT in behaviors
5HT and Behaviors:
We will now proceed to discuss the behaviors which are affected, modified changed or controlled by
5HT
There are some very important behaviors regulated by 5HT ranging from temperature regulation to
sleep, anxiety and depression
1. Temperature regulation: temperature regulation is an important motivational behavior dependent on
the day and night cycles. If 5HT is injected intraventrically it leads to increased body temperature.
PCPA is injected to deplete brain serotonin and after this depletion, raphe nuclei are electrically
stimulated no rise in body temperature take place. The body temperature would otherwise rise with the
stimulation of raphe nuclei (increased serotnonin,leads to increasedbody temperature).
2. Sensory perception: 5HT involved in producing the heightened sensory and visuomotor
hallucinogenic effect of LSD. We have talked about LSD effects take place through the serotonergic
system. Injections of PCPA(which depletes brain serotonin), reduced motor activity, and reduced
emotional reactivity, but increased sensitivity to pain (means that in rats the electrical current given for a
response is much lower-they respond at a lower current with avoidance and other behaviors). Further,
when 5HT levels are decreased this slows down the process of tolerance to morphine (tolerance means
that the effectiveness of drug dosage is lessened, so the dosage has to be increased to have the same
effect of response).
3. Serotonin and sleep
Evidence for involvement of 5HT in sleep is provided by experiments in which levels of 5HT are
increased by administration of MOAI (reduced deactivation) or 5HTP (increased enzymes) or 5HT. This
treatment leads to an increase in levels of 5HT and also increase time spent in Slow Wave Sleep (SWS).
If 5HT is decreased then the time spent in SWS is also decreased.
PCPA administration (depletes/reduces 5HT drastically) also leads to reduced Rapid Eye Movement
sleep (REM)
Jouvet (1973) was the first one to identify the relationship between 5HT and sleep. Jouvet carried out
experiments of manipulating raphe nuclei and seeing its effect in cats. (Why cats are best animals for
sleep research as they spend 2/3rd of their life in sleep). The electrolytic lesion of the Raphe nuclei led to
132
img/92-35_files/92-3500002im.jpg" width="718" height="1067" useMap="#Map">
Neurological Basis of Behavior (PSY - 610)
VU
decreased 5HT and decreased time spent in sleep. Sleep reduced when 5HT was reduced 85% time in
sleep was reduced to 20% (insomniac cats!!)
Further when PCPA was injected, 1-2 days after injection ( when complete depletion of brain 5HT has
taken place) increases insomnia followed. How was this confirmed? By injections of 5HTP (which
increased 5HT and reverses PCPA induced lower levels of 5HT, insomnia induced by PCPA was
reversed!
4. Other behaviours
a) 5HT appears to be involved in Depression as there is evidence of decreased 5HT and 5HIAA ( 5HT
metabolite) in brains of suicide victims ( Bourne et al 1968). This indicates that in depression 5HT is
lower than normal levels (antidepressant such as tricyclics and MOAI also act to increase levels of 5HT)
b) Decreases in 5 HT leads to a disinhibition of behaviors (reduced controls on behaviors), increased
impulsivity, increased aggressiveness, and increased suicidal tendencies.
c) Serotonin is also involved in control of sexual and reproductive behaviors. PCPA which depletes
5HT, increased sex drive in males. In females, the ovulation cycle is blocked by narcotics; this blockade
is removed by administration of 5HT
Thus, we have seen that 5HT is one of the major neurotransmitters which influences a wide range of
motivational and other behaviors.
Acetylcholine: ACH
One of the major neurotransmitters a class by itself, as there is no other like this neurotransmitter. This
NT has been well known and around since 1920's. The effects of ACH have been studied in Bioassay
and neuromuscular transmission (frog muscles contraction when Ach is applied on the muscle in the
experimental solution) demonstrated.Ach is used by neurons which terminate on the neuromuscular
junction. Since the 1960's there have been studies suing enzymatic, gas chromatography, flourometric
and other studies demonstrating the involvement of Ach in brain-behavior modulation. This is classified
as an excitatory NT. Excitatory post synaptic Potentials are released in the muscle cell. ACH has an
excitatory effect on the skeletal muscles, but it is inhibitory at heart (remember we earlier told you that
the location is as important as the classification of the NT for its actions as excitatory or inhibitory
neurotransmitter). ACH is also found to play an active role in brain areas such as hypothalamus and
cerebral cortex. It is involved in learning and memory (known as the memory molecule), and Rapid eye
Movement sleep.
The study of Ach is easier than other neurotransmitters as it is easy to remove and study outside the
brain in petri dish. The nicotinic receptors was the first receptor identified (Agranoff,  p205)..
Acetylcholine is found in ganglions of the autonomic nervous system and the target organs of
parasympathetic nervous system.
This has two distinctive types of receptors the nicotinic- which connects the muscle fibers and works
through sodium channels (these are ionotropic receptors). Curare, a poison can block the transmission of
Ach at neuromuscular joints. In neuromuscular joints nicotine mimics excitatory effects of ACH
The muscarinic that are found in the CNS and these use G proteins, cyclic AMPs as second messengers.
These are classified as metabotropic receptors. Atropine blocks these receptors, this leads to loss of
memory (Pinel 2002, p. 95-102)
133
img/92-35_files/92-3500003im.jpg" width="718" height="1067" useMap="#Map">
Neurological Basis of Behavior (PSY - 610)
VU
The ACH receptors are known as the cholinergic receptors
Synthesis
Acetylcholine is synthesized in a catalytic action of cholinesterase on the Co-enzyme A + its acetate ion
and Choline. It acts to detach acetate ion from co-enzyme A and attach it with choline to form
acetylcholine and separate the Co Enzyme A. The Co Enzyme A is found in Vitamin B, and choline is
broken down from lipids and Acetyl is an acetate ion. Choline is the rate limiting factor of ach (no
choline, no Ach)
The Ach is further broken down by these enzymes Choline acetyl transferase whereby. Ach is broken
down into choline and acetyl via a process of hydrolysis
Half of choline in this chemical action is retrieved and recycled
Involvement and neuroanatomical sites of ACH
Ach is formed in the cell bodies of the neuron and transported to the neuromuscular junctions. It is
released by action potential, crosses over and activates the muscles fiber.
I a) Acetylcholine is found at all neuromuscular junctions, autonomic ganglion and parasympathetic
systems
b) Hippocampus receives Ach input from medial septal nucleus
c) Ach projects into the ascending reticular arousal system
d) Involved in Auditory and Visual systems
e) Found in the Caudate nucleus
f) Found in Ventral basal hypothalamus
g) In Suproptic nucleus brain stem
h) Ach acts as a sensory transmitter in thermal receptor. Pain is produced by directly putting Ach on to a
blister on the skin.
II Ach is involved in the:
a) Release of catecholamines (works to balance other NT's and has interaction with DA, NE, and 5HT
in all functions)
b) Conduction of signals: it acts in the axonal conduction by depolarizing the axon.
Steps in ACH synthesis where drugs can modulate action
Drugs affecting cholinergic synapses
Step 1. Synthesis: Ach Synthesis can be blocked by styryl pyridine- a derivative
Step 2. Release of Ach from the presynaptic membrane is enhanced by B-bungarotoxin and black
widow spider venom and blocked by butolinus toxin-deadly food poison. The latter acts to block Ach
transmission leading to total paralysis
Step 3. Post receptor sites can be activated or blocked in both type of receptors
These are activated by Ach agonists or cholinometic drugs and anticholinesterases (blocking the enzyme
which breaks down Ach)
a) Nicotinic receptors are blocked by A- Bungarotoxin and Curare (Tubocurarine). Local anesthetics
and drugs such as phencyclidine bind to these receptors to modulate action.
Curare, a poison used by South American Indians in arrows prevents Ach from reaching post receptor
area (occupies the sites), since the muscles do not get activated, this lead to blockade of all muscular
134
img/92-35_files/92-3500004im.jpg" width="718" height="1067" useMap="#Map">
Neurological Basis of Behavior (PSY - 610)
VU
responses. Since there is no post synaptic response, no nerve command is processed. This leads to total
paralysis of muscles. Poison from cobra, Alpha bungarotoxin acts through this mechanism
b) Muscarinic receptors are blocked by atropine (belladona), and scopolamine
Step 4. Presynaptic receptor blockade: Atropine and scopolamine block these
Step 5. Inhibition of inactivation activity leads to increase in ACH in the brain by physostigmine which
blocks the acteylcholinesterase breaking down of Ach. This leads to increased levels of Ach in the
system, resulting in repeated stimulation of muscles. This means that the muscles would be repeatedly
stimulated. This results in violent muscular contractions.
It is reported by (Brown and Wallace, p 40) that there is a West Indian tribal custom where Calabar bean
extract is used to find if a person is guilty or innocent. If guilty, then the person who had taken the bean
extract as a test would die, and if they were innocent the person would swallow and vomit.
Physostigmine is used as a therapy for Myasthenia Gravis: (neurological disorder where the muscles
are extremely weak, and don't have normal levels of ACH- for muscles to act). The drugs given
increase ACH (cholinometics, or anticholinesterases). Increases in Ach using this therapy can lead to
nightmares, confusion and hallucination.
Receptor Agonists: a) muscarinic receptors are affected by muscarinic agonists. One of them is the
muscarinic extract from poison mushrooms, which if taken increases ACH activity leads to increased
sweating, increased salivation, constriction of pupils and decreased heart rate. Also muscarine, which
mimics the inhibitory effects of ACH (Agranoff 1989), b) Nicotinic receptor agonists, in neuromuscular
joints, nicotine mimics the excitatory effects of ACH
Nicotinic agonists could be useful in the treatment of a variety of neurological disorders including
Alzheimer's disease, Parkinson's disease and chronic pain.
Receptor Antagonists:
a) For Muscarinic receptors: Atropine is an antagonist for muscarinic receptors. Atropine Belladonna-
night shade poison- blocks muscarinic receptors, acts as a false transmitter. It occupies the post receptor
sites and does not transmit message forward it cannot, it is a false molecule). Atropine belladonna liquid
leads to dilation of pupils when applied directly on to the eyes. Why Belladonna (beautiful woman)
because women used to apply it to their eyelids for wider eye look. From Grecian times, Hippocretes
used it for stomach ailments and cosmetics. In 1880's, the breakdown of atropine from the belladonna
plant­ affects the muscarinic receptor
Atropine and Scopolamine lead to decreased ACH in the brain leading to amnesia (reduced ACH in
Alzheimer brain related to their memory loss). This also indicates that ACH is involved in learning and
memory.
Muscarinic antagonists are used to control and prevent vomiting, are also useful for the treatment of
Parkinson's disease. In large doses however, the muscarinic antagonists cause severe side effects such as
hallucinations and memory disturbances.
Step 6. Choline uptake. B-Bungarotoxin and black spider widow venom
Check table 1 taken from the website, it provides a very good summary of the agonists and antagonist
we have referred to above
135
img/92-35_files/92-3500005im.jpg" width="718" height="1067" useMap="#Map">
Neurological Basis of Behavior (PSY - 610)
VU
Table1: Natural Cholinergic Agonist and Antagonists
Agonists
Source of Compound
Mode of Action
Activates nicotinic class
Alkaloid prevalent in the
Nicotine
of ACh receptors, locks
tobacco plant
the channel open
Alkaloid  produced  by
Activates
muscarinic
Muscarine
Amanita
muscaria
class of ACh receptors
mushrooms
Induces  massive  ACh
Protein produced by the
release,
possibly
by
a-Latrotoxin
Ca2+
black widow spider
acting
as
a
ionophore
Antagonists
Atropine (and related
Alkaloid produced by the
Blocks ACh actions only
compound
deadly
nightshade,
at muscarinic receptors
Scopolamine)
Atropa belladonna
Eight proteins produced
Inhibits the release of
Botulinus Toxin
by
Clostridium
ACh
botulinum
Protein  produced
by
Prevents ACh receptor
a-Bungarotoxin
Bungarus
genus
of
channel opening
snakes
Prevents ACh receptor
Active
ingredient
of
d-Tubocurarine
channel opening at motor
curare
end-plate
Source: http://web.indstate.edu/thcme/mwking/nerves.html#ach
References:
1. Kalat J.W (1998) Biological Psychology Brooks/ Cole Publishing
2. Carlson N.R. (2005) Foundations of Physiological Psychology Allyn and Bacon, Boston
3. Pinel, John P.J. (2003) Biopsychology (5th edition) Allyn and Bacon Singapore
4 Bloom F, Nelson and Lazerson (2001), Behavioral Neuroscience: Brain, Mind and Behaviors (3rd
edition) Worth Publishers New York
5. Bridgeman, B (1988) The Biology of Behavior and Mind. John Wiley and Sons New York
6. Brown,T.S. and Wallace.(1980) P.M Physiological Psychology
136
img/92-35_files/92-3500006im.jpg" width="718" height="1067" useMap="#Map">
Neurological Basis of Behavior (PSY - 610)
VU
Academic Press New York
7. Seigel, G.J. (Ed. in chief) Agranoff, B.W, Albers W.R. and Molinoff, P.B. (Eds) (1989) Basic
Neurochemistry: Molecular, Cellular and Medical Aspects
8. Cooper,J.R, F.E Bloom,and R.H Roth (1996) Biochemical basis of neuropharmacology 7th Edition,
OUP
9. Pharmacology, Biochemistry and behavior
(Additional references for the module: Iversen and Iversen, Gazzaniga, Bloom, and handouts)
Note: References 3, 8, 9 more closely followed in addition to the references cited in text.
137